115 related articles for article (PubMed ID: 37606035)
1. Buthionine sulfoximine and chemoresistance in cancer treatments: a systematic review with meta-analysis of preclinical studies.
Dos Reis Oliveira C; Pereira JC; Barros Ibiapina A; Roseno Martins IR; de Castro E Sousa JM; Ferreira PMP; Carneiro da Silva FC
J Toxicol Environ Health B Crit Rev; 2023 Nov; 26(8):417-441. PubMed ID: 37606035
[TBL] [Abstract][Full Text] [Related]
2. Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian-carcinoma cell lines.
Mistry P; Loh SY; Kelland LR; Harrap KR
Int J Cancer; 1993 Nov; 55(5):848-56. PubMed ID: 8244583
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.
O'Dwyer PJ; Hamilton TC; LaCreta FP; Gallo JM; Kilpatrick D; Halbherr T; Brennan J; Bookman MA; Hoffman J; Young RC; Comis RL; Ozols RF
J Clin Oncol; 1996 Jan; 14(1):249-56. PubMed ID: 8558205
[TBL] [Abstract][Full Text] [Related]
4. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine.
Kramer RA; Greene K; Ahmad S; Vistica DT
Cancer Res; 1987 Mar; 47(6):1593-7. PubMed ID: 3815359
[TBL] [Abstract][Full Text] [Related]
5. Synergistic effect of buthionine sulfoximine on the chlorin e6-based photodynamic treatment of cancer cells.
Lee HM; Kim DH; Lee HL; Cha B; Kang DH; Jeong YI
Arch Pharm Res; 2019 Nov; 42(11):990-999. PubMed ID: 31482490
[TBL] [Abstract][Full Text] [Related]
6. L-S,R-buthionine sulfoximine: historical development and clinical issues.
Bailey HH
Chem Biol Interact; 1998 Apr; 111-112():239-54. PubMed ID: 9679558
[TBL] [Abstract][Full Text] [Related]
7. Effects of glutathione depletion by buthionine sulfoximine on the sensitivity of EMT6/SF cells to chemotherapy agents or X radiation.
Shrieve DC; Harris JW
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1171-4. PubMed ID: 3744936
[TBL] [Abstract][Full Text] [Related]
8. Chemosensitization by buthionine sulfoximine in vivo.
Tsutsui K; Komuro C; Ono K; Nishidai T; Shibamoto Y; Takahashi M; Abe M
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1183-6. PubMed ID: 2427490
[TBL] [Abstract][Full Text] [Related]
9. Overcoming tumor necrosis factor-alpha resistance of human renal and ovarian carcinoma cells by combination treatment with buthionine sulfoximine and tumor necrosis factor-alpha. Role of tumor necrosis factor-alpha mRNA down-regulation in tumor cell sensitization.
Mizutani Y; Yoshida O
Cancer; 1994 Feb; 73(3):730-7. PubMed ID: 8299097
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.
Bailey HH; Mulcahy RT; Tutsch KD; Arzoomanian RZ; Alberti D; Tombes MB; Wilding G; Pomplun M; Spriggs DR
J Clin Oncol; 1994 Jan; 12(1):194-205. PubMed ID: 8270977
[TBL] [Abstract][Full Text] [Related]
11. Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells.
Kisara S; Furusawa S; Murata R; Ogata M; Hikichi N; Takayanagi Y; Sasaki K
Oncol Res; 1995; 7(3-4):191-200. PubMed ID: 8555653
[TBL] [Abstract][Full Text] [Related]
12. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione.
Ozols RF; Louie KG; Plowman J; Behrens BC; Fine RL; Dykes D; Hamilton TC
Biochem Pharmacol; 1987 Jan; 36(1):147-53. PubMed ID: 3801051
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of azathioprine plus buthionine sulfoximine in the treatment of human hepatocarcinoma and colon carcinoma.
Hernández-Breijo B; Monserrat J; Ramírez-Rubio S; Cuevas EP; Vara D; Díaz-Laviada I; Fernández-Moreno MD; Román ID; Gisbert JP; Guijarro LG
World J Gastroenterol; 2011 Sep; 17(34):3899-911. PubMed ID: 22025878
[TBL] [Abstract][Full Text] [Related]
14. Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis.
Lewis-Wambi JS; Kim HR; Wambi C; Patel R; Pyle JR; Klein-Szanto AJ; Jordan VC
Breast Cancer Res; 2008; 10(6):R104. PubMed ID: 19061505
[TBL] [Abstract][Full Text] [Related]
15. Effects of buthionine sulfoximine treatment on cellular glutathione levels and cytotoxicities of cisplatin, carboplatin and radiation in human stomach and ovarian cancer cell lines.
Lee KS; Kim HK; Moon HS; Hong YS; Kang JH; Kim DJ; Park JG
Korean J Intern Med; 1992 Jul; 7(2):111-7. PubMed ID: 1306072
[TBL] [Abstract][Full Text] [Related]
16. Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine.
Maeda H; Hori S; Ohizumi H; Segawa T; Kakehi Y; Ogawa O; Kakizuka A
Cell Death Differ; 2004 Jul; 11(7):737-46. PubMed ID: 15002036
[TBL] [Abstract][Full Text] [Related]
17. Effect of buthionine sulfoximine and ethacrynic acid on cytotoxic activity of mitomycin C analogues BMY 25282 and BMY 25067.
Xu BH; Singh SV
Cancer Res; 1992 Dec; 52(23):6666-70. PubMed ID: 1423311
[TBL] [Abstract][Full Text] [Related]
18. Toxic effects of acute glutathione depletion by buthionine sulfoximine and dimethylfumarate on murine mammary carcinoma cells.
Dethlefsen LA; Lehman CM; Biaglow JE; Peck VM
Radiat Res; 1988 May; 114(2):215-24. PubMed ID: 3375425
[TBL] [Abstract][Full Text] [Related]
19. Buthionine sulfoximine enhances glutathione-but attenuates glutamate-stimulated cell proliferation.
Kang YJ
Cell Mol Biol Res; 1995; 41(2):131-6. PubMed ID: 8581064
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of EMT6/SF tumor cell killing by mitomycin C and cyclophosphamide following in vivo administration of buthionine sulfoximine.
Ono K; Shrieve DC
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1175-8. PubMed ID: 3091546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
